<DOC>
	<DOC>NCT02200666</DOC>
	<brief_summary>The purpose of the investigation is to confirm the following under the post-marketing actual use of Forxiga Tablets (hereinafter referred to as Forxiga). - Development of ADRs specified as Key Investigation Items and the risk factors - Contributing factors possibly having an impact on the safety and efficacy - Development of ADRs unexpected from the Precautions for use and ADRs under actual drug use</brief_summary>
	<brief_title>Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Patients treated with Forxiga for the first time due to type 2 diabetes mellitus, which is the indication of the drug.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Forxiga</keyword>
	<keyword>Long-term use</keyword>
</DOC>